Regulatory and other responses to the pharmaceutical opioid problem

Gabrielle Campbell, Briony Larance and Nicholas Lintzeris
Med J Aust 2019; 211 (5): . || doi: 10.5694/mja2.50303
Published online: 2 September 2019

In reply: In response to our recent perspective article, in which we discuss Australian responses to the pharmaceutical opioid problem,1 Polasek and colleagues enquire why we do not refer to the potential of pharmacogenomics in identifying patients at increased risk of opioid toxicity. We agree that precision pain medicine based on genomic profile is an interesting approach, but it was not discussed for several reasons.

  • Gabrielle Campbell1
  • Briony Larance1,2
  • Nicholas Lintzeris3,4

  • 1 National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW
  • 2 University of Wollongong, Wollongong, NSW
  • 3 University of Sydney, Sydney, NSW
  • 4 Drug and Alcohol Services, South Eastern Sydney Local Health District, Sydney, NSW


Competing interests:

No relevant disclosures.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.